| dc.contributor.author |
Chitkara, Deepak |
|
| dc.contributor.author |
Mittal, Anupama |
|
| dc.date.accessioned |
2024-01-04T10:34:39Z |
|
| dc.date.available |
2024-01-04T10:34:39Z |
|
| dc.date.issued |
2019-04 |
|
| dc.identifier.uri |
https://www.future-science.com/doi/abs/10.4155/tde-2018-0074 |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13662 |
|
| dc.description.abstract |
The current study aims to co-deliver docetaxel (DTX) and alpha-lipoic acid (ALA) using solid lipid nanoparticles (SLNs) as a carrier for the treatment of breast cancer. Methods: Computational analysis was used to screen different solid lipids as carriers, following which SLNs were prepared and characterized. Furthermore, antioxidant activity assays and cell culture studies were performed. Results:In vitro assessment in 4T1 (murine mammary carcinoma) and MCF-7 (human breast adenocarcinoma) cells revealed enhanced efficacy of the co-loaded SLNs as compared with free drugs and single drug-loaded SLNs. Increased apoptosis following treatment with DTX-ALA co-loaded SLN was also observed |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
Future Science Group |
en_US |
| dc.subject |
Pharmacy |
en_US |
| dc.subject |
Breast cancer |
en_US |
| dc.subject |
Solid lipid nanoparticles (SLNs) |
en_US |
| dc.subject |
Cellular uptake |
en_US |
| dc.title |
Docetaxel and alpha-lipoic acid co-loaded nanoparticles for cancer therapy |
en_US |
| dc.type |
Article |
en_US |